#1 Clinical Trials Search in Europe

Tenofovir Disoproxil

This article explores the use of Tenofovir Disoproxil, a potent antiviral medication, in clinical trials for the treatment of chronic hepatitis B. We’ll examine its effectiveness, safety profile, and potential benefits compared to other treatments across various patient populations and study designs.

Table of Contents

What is Tenofovir Disoproxil?

Tenofovir Disoproxil is a medication used in the treatment of viral infections. It belongs to a class of drugs called nucleotide analogs, which work by inhibiting the replication of certain viruses in the body[1]. This drug is also known by its brand names, which include Viread and Virehepa[5].

What Conditions Does Tenofovir Disoproxil Treat?

Tenofovir Disoproxil is primarily used to treat two main conditions:

  • Chronic Hepatitis B (CHB): This is a viral infection that affects the liver, causing inflammation and potentially leading to liver damage over time[4][5].
  • Human Immunodeficiency Virus (HIV) Infection: HIV is a virus that attacks the body’s immune system. If left untreated, it can lead to AIDS (Acquired Immunodeficiency Syndrome)[2].

Additionally, Tenofovir Disoproxil is used in HIV prevention strategies:

  • Pre-Exposure Prophylaxis (PrEP): This is a preventive measure where the drug is taken by individuals at high risk of HIV exposure to reduce their chances of contracting the virus[2].
  • Post-Exposure Prophylaxis (PEP): This involves taking the medication shortly after potential exposure to HIV to prevent infection[7].

How Does Tenofovir Disoproxil Work?

Tenofovir Disoproxil works by inhibiting the action of specific enzymes that viruses need to replicate:

  • For HIV, it inhibits the reverse transcriptase enzyme[1].
  • For Hepatitis B virus (HBV), it inhibits the HBV polymerase[1].

By blocking these enzymes, Tenofovir Disoproxil prevents the viruses from multiplying and spreading in the body. This helps to reduce the viral load (amount of virus in the body) and, in the case of HBV, can lead to improvements in liver health[4].

Available Formulations

Tenofovir Disoproxil is available in different formulations:

  • Tenofovir Disoproxil Fumarate (TDF): This is a common form of the drug, often prescribed as a 300mg tablet[2][4].
  • Tenofovir Disoproxil: This formulation is available as a 245mg tablet[5].
  • Combination Tablets: Tenofovir Disoproxil is often combined with other antiviral medications in single tablets for easier dosing. Examples include:
    • Tenofovir + Emtricitabine (known as Truvada)[2]
    • Tenofovir + Emtricitabine + Rilpivirine[3]

Clinical Studies and Efficacy

Several clinical studies have demonstrated the effectiveness of Tenofovir Disoproxil:

  • For Chronic Hepatitis B: Studies have shown that Tenofovir Disoproxil can effectively suppress HBV replication. In one study, 65% of patients achieved undetectable HBV DNA levels (less than 400 copies per milliliter) after 48 weeks of treatment[5].
  • For HIV Treatment: Tenofovir Disoproxil, when used as part of combination antiretroviral therapy, has shown to be effective in suppressing HIV viral load. It’s often used in first-line treatment regimens[3].
  • For HIV Prevention (PrEP): Studies have demonstrated that when taken consistently, Tenofovir Disoproxil (usually in combination with Emtricitabine) can significantly reduce the risk of HIV infection in high-risk individuals[2].

Potential Side Effects

While Tenofovir Disoproxil is generally well-tolerated, it can cause side effects in some people. Common side effects may include:

  • Nausea
  • Diarrhea
  • Headache
  • Fatigue

More serious but less common side effects can include kidney problems and decreased bone density. Regular monitoring by a healthcare provider is important to detect and manage any potential side effects[2][7].

Usage in Combination Therapies

Tenofovir Disoproxil is often used in combination with other antiviral medications. This approach, known as combination therapy, is particularly important in HIV treatment to prevent the development of drug resistance. Some examples of combination therapies include:

  • For HIV Treatment: Tenofovir Disoproxil + Emtricitabine + Rilpivirine. This combination provides a complete HIV treatment regimen in a single daily pill[3].
  • For HIV Prevention (PrEP): Tenofovir Disoproxil + Emtricitabine (Truvada). This combination is approved for use as PrEP in individuals at high risk of HIV exposure[2].
  • For Post-Exposure Prophylaxis (PEP): Tenofovir Disoproxil + Emtricitabine + either Lopinavir/Ritonavir or Maraviroc. These combinations are used as emergency treatment to prevent HIV infection after potential exposure[7].

It’s important to note that the specific combination and dosage should always be determined by a healthcare provider based on individual patient factors and the most current treatment guidelines.

Aspect Details
Primary Use Treatment of chronic hepatitis B
Mechanism of Action Inhibits HBV polymerase, reducing viral replication
Efficacy Measures HBV DNA suppression, HBsAg reduction, ALT normalization
Safety Monitoring Kidney function, bone density, liver enzymes
Patient Populations Treatment-naive and experienced adults, pregnant women
Comparative Studies Versus Entecavir, Tenofovir Disoproxil Fumarate
Potential Benefits High barrier to resistance, potential for HBsAg loss
Duration of Treatment Typically long-term, often 48 weeks or more in trials

FAQ

  • What is Tenofovir Disoproxil and how does it work? Tenofovir Disoproxil is a nucleotide analogue that inhibits hepatitis B virus (HBV) growth. It works by blocking an enzyme called HBV polymerase, which is essential for the virus to replicate. This helps to reduce the amount of HBV in the body and slow down liver damage.
  • How effective is Tenofovir Disoproxil in treating chronic hepatitis B? Clinical trials have shown Tenofovir Disoproxil to be highly effective in treating chronic hepatitis B. It has demonstrated potent antiviral activity, with many patients achieving undetectable HBV DNA levels and improvements in liver function. Some studies have also shown potential for reducing hepatitis B surface antigen (HBsAg) levels, which is an important marker of the disease.
  • Are there any side effects associated with Tenofovir Disoproxil? Like all medications, Tenofovir Disoproxil can have side effects. Common side effects may include nausea, diarrhea, and headache. In some cases, it may affect kidney function or bone density. Clinical trials closely monitor patients for these and other potential side effects to ensure the drug's safety profile is well understood.
  • How does Tenofovir Disoproxil compare to other hepatitis B treatments? Clinical trials have compared Tenofovir Disoproxil to other hepatitis B treatments like Entecavir and Tenofovir Disoproxil Fumarate. These studies aim to determine if Tenofovir Disoproxil offers any advantages in terms of efficacy, safety, or resistance profile. Some trials have shown promising results, but more research is needed to fully establish its comparative effectiveness.
  • Can Tenofovir Disoproxil be used in pregnant women with hepatitis B? Some clinical trials have investigated the use of Tenofovir Disoproxil in pregnant women with chronic hepatitis B. These studies aim to determine the optimal timing of treatment during pregnancy to prevent mother-to-child transmission of HBV. While initial results seem promising, it's important for pregnant women to discuss the potential risks and benefits with their healthcare provider.

Ongoing Clinical Trials on Tenofovir Disoproxil

  • Study comparing ALG-000184 with tenofovir disoproxil in untreated adults with chronic hepatitis B virus infection

    Recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria France Italy Romania Spain

  • Study on the Effects and Safety of Ianalumab in Adults with Lupus Nephritis Who Completed Previous Treatment

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Czechia France Hungary Romania Spain

  • Study on the Effectiveness and Safety of Ianalumab for Patients with Diffuse Cutaneous Systemic Sclerosis

    Recruiting

    1 1
    Investigated drugs:
    Austria Belgium France Germany Greece Hungary +4

  • Study Comparing Doravirine and Dolutegravir-Based Treatments for People with HIV-1 Who Have Not Yet Started Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    France

  • Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

    Recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia France Germany Hungary Italy +5

  • Study on the Effectiveness of Doravirine, Tenofovir Disoproxil, and Lamivudine in HIV Patients with M184V/I Mutation and Controlled Viral Load

    Recruiting

    1 1 1
    Investigated drugs:
    France

  • Study on the Effects and Safety of Bulevirtide, Peginterferon Alfa-2a, and Entecavir in Patients with Chronic Hepatitis D

    Recruiting

    1 1 1 1
    Investigated drugs:
    Sweden

  • Phase 3 study of ianalumab plus standard drug combination in adults and adolescents with systemic lupus erythematosus

    Not recruiting

    1 1 1
    Investigated drugs:
    Bulgaria Czechia Hungary Poland Portugal Slovakia +1

  • Study on Stopping Tenofovir Alafenamide, Tenofovir Disoproxil, and Entecavir in Patients with Chronic Hepatitis B

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium

  • Study on Dolutegravir and Lamivudine for Maintaining Viral Control in Children with HIV Aged 2 to Under 15 Years

    Not recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Hepatitis B virus (HBV): A viral infection that attacks the liver and can cause both acute and chronic disease. Chronic HBV infection can lead to serious liver damage, including cirrhosis and liver cancer.
  • Chronic hepatitis B: A long-lasting liver infection caused by the hepatitis B virus. It is diagnosed when a person tests positive for the hepatitis B surface antigen (HBsAg) for more than six months.
  • Nucleotide analogue: A type of antiviral medication that mimics the building blocks of DNA to interfere with viral replication. Tenofovir Disoproxil is an example of a nucleotide analogue used to treat hepatitis B.
  • HBV DNA: The genetic material of the hepatitis B virus. Measuring HBV DNA levels in the blood helps to assess the amount of virus present and monitor treatment effectiveness.
  • Hepatitis B surface antigen (HBsAg): A protein on the surface of the hepatitis B virus. Its presence in the blood indicates current HBV infection.
  • HBeAg: Hepatitis B e antigen, a protein produced by the hepatitis B virus. Its presence usually indicates that the virus is actively replicating.
  • Seroconversion: The development of antibodies in the blood as a result of infection or vaccination. In hepatitis B, it can refer to the loss of HBeAg and development of anti-HBe antibodies, or the loss of HBsAg and development of anti-HBs antibodies.
  • Viral load: The amount of virus in an infected person's blood. In hepatitis B, it is typically measured by quantifying HBV DNA levels.
  • Alanine aminotransferase (ALT): An enzyme found primarily in the liver. Elevated levels in the blood can indicate liver damage or inflammation.
  • Virological breakthrough: An increase in HBV DNA levels during antiviral treatment, often indicating the development of drug resistance.

References

  1. https://clinicaltrials.gov/study/NCT00823342
  2. https://clinicaltrials.gov/study/NCT02968576
  3. https://clinicaltrials.gov/study/NCT02104700
  4. https://clinicaltrials.gov/study/NCT01711567
  5. https://clinicaltrials.gov/study/NCT03485534
  6. https://clinicaltrials.gov/study/NCT01671787
  7. https://clinicaltrials.gov/study/NCT01533272